Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Among the most extensively engineered families of research peptides, growth hormone-releasing hormone (GHRH) analogs illustrate how a single short native sequence — the first 29 residues of endogenous GHRH — can be progressively modified to alter half-life, enzymatic resistance, and pulsatility profile. A focused GHRH analog comparison across the four most-studied research-grade molecules — Sermorelin, Tesamorelin, CJC-1295 (No DAC, also known as Mod GRF 1-29), and CJC-1295 with DAC — reveals how iterative peptide chemistry shapes pharmacokinetic behavior at the GHRH receptor.
All four compounds share the same fundamental mechanism: agonism of the GHRH receptor (GHRHR), a Class B G protein-coupled receptor expressed predominantly on somatotrophs in the anterior pituitary, leading to cyclic AMP elevation and downstream stimulation of growth hormone synthesis and pulsatile release. Where they diverge is in chemical structure — and these structural choices have substantial consequences for plasma half-life, dosing frequency in preclinical research, and the temporal pattern of induced GH secretion.
GHRH Receptor Biology
Native human GHRH is a 44-amino-acid peptide secreted in pulses from the hypothalamic arcuate nucleus into the hypophyseal portal system, where it acts on pituitary somatotrophs to stimulate growth hormone synthesis and release. The biologically active region resides in the N-terminal 29 amino acids; the C-terminal residues 30–44 modulate receptor binding affinity and stability but are not required for receptor activation. This biological observation set the stage for the development of GHRH(1-29) as the minimum effective fragment — the molecule now known as Sermorelin.
The plasma half-life of native GHRH and unmodified GHRH(1-29) is short — typically estimated at less than 10 minutes — due to rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), which cleaves at the Ala²-Asp³ bond, and trypsin-like proteases. The history of GHRH analog development has therefore been driven by structural modifications that confer enzymatic resistance, extend half-life, and optimize the dosing profile.
The GHRH receptor (GHRHR) is a Class B G protein-coupled receptor closely related to the receptors for glucagon, GLP-1, GLP-2, GIP, secretin, calcitonin, parathyroid hormone, and corticotropin-releasing hormone. Class B GPCRs share a distinctive architecture: an extracellular N-terminal domain that captures the C-terminal portion of the peptide ligand, and a seven-transmembrane domain that engages the N-terminal portion. This “two-domain” binding model explains why N-terminal modifications (such as DPP-4 resistance substitutions) often preserve receptor binding affinity while shielding the N-terminus from enzymatic attack. The downstream signaling cascade through Gαs and adenylate cyclase elevates intracellular cAMP, activating protein kinase A and downstream transcription factors that drive growth hormone gene expression and pulsatile release.
GHRHR expression is concentrated in pituitary somatotrophs but is also detectable in extra-pituitary tissues including the placenta, ovaries, testis, immune cells, and some tumor cell lines. This wider tissue distribution underlies some of the research interest in GHRH analogs beyond growth hormone biology, including investigations of immune modulation and cellular proliferation in non-pituitary contexts. For most preclinical research applications, however, the pituitary somatotroph response remains the dominant readout.
Compound-by-Compound Comparison
1. Sermorelin (GHRH 1-29)
Sermorelin is the shortest fully active synthetic GHRH analog: an unmodified 29-amino-acid C-terminal amidated peptide corresponding to the N-terminal active region of human GHRH. Walker et al. (1990) characterized the bioactivity of GHRH(1-29) analogs after subcutaneous administration and confirmed that the 1-29 fragment retains full agonist activity at the GHRHR [1]. Because it lacks DPP-4-resistance modifications, Sermorelin has a short plasma half-life (estimated at 10–20 minutes), making it useful in research as a relatively “physiological” probe of GHRH receptor activation. Prakash and Goa (1999) reviewed its use as a diagnostic agent in growth hormone deficiency research, where its short duration of action enables clean characterization of pituitary somatotroph reserve [2]. Thorner et al. (1986) provided foundational characterization of GHRH(1-29)NH₂ pharmacokinetics and pituitary responsiveness, establishing the baseline against which all subsequent GHRH analog research is interpreted [9]. Research-grade Sermorelin is commonly used in studies of pulsatile GH secretion and as a comparative reference point against longer-acting analogs.
2. Tesamorelin
Tesamorelin (originally designated TH9507) is a synthetic GHRH analog consisting of the full 44-amino-acid GHRH sequence with the addition of a trans-3-hexenoyl group at the N-terminus. This N-terminal lipid moiety confers substantial resistance to DPP-4 cleavage and modestly extends plasma half-life relative to unmodified GHRH. Spooner and Mohammed (2012) reviewed Tesamorelin’s pharmacology and clinical research history, noting that the structural modification extends biological activity sufficiently to enable once-daily dosing in research and clinical protocols [3]. Falutz et al. (2007) and subsequent investigators published a series of randomized controlled trials establishing the efficacy of Tesamorelin in reducing visceral adipose tissue in HIV-associated lipodystrophy. Stanley et al. (2014) reported that Tesamorelin administration was associated with improvements in liver fat content in research participants with HIV and non-alcoholic fatty liver disease, expanding the metabolic research applications of this compound [10]. Research-grade Tesamorelin is used in preclinical studies of GH/IGF-1 axis biology and metabolic research focused on visceral adiposity models.
3. CJC-1295 (No DAC) — Modified GRF 1-29 (Mod GRF 1-29)
CJC-1295 without DAC — frequently referred to in the research literature as Mod GRF 1-29 — is a tetrasubstituted analog of GHRH(1-29) with four amino acid substitutions designed to confer enzymatic stability and improved receptor binding: D-Ala² (DPP-4 resistance), Gln⁸ (acid stability), Ala¹⁵ (bioactivity enhancement), and Leu²⁷ (resistance to trypsin-like cleavage). Despite these stabilizing modifications, Mod GRF 1-29 has a relatively short plasma half-life of approximately 30 minutes — substantially longer than unmodified Sermorelin, but still short enough to preserve the natural pulsatile pattern of GH release when administered without an albumin-binding moiety. This characteristic makes Mod GRF 1-29 particularly useful in research designs that aim to study GH pulsatility while minimizing tonic baseline elevation of GH. The D-Ala² substitution, in particular, exemplifies the medicinal-chemistry principle that a single position-2 modification can confer dramatic DPP-4 resistance — a principle later applied across the entire incretin and neuropeptide research peptide landscape.
4. CJC-1295 with DAC
CJC-1295 with DAC is Mod GRF 1-29 with an additional drug affinity complex (DAC) moiety — a maleimidopropionic acid (MPA) group attached at the C-terminus — that covalently and irreversibly binds to a free cysteine residue (Cys-34) on circulating serum albumin shortly after administration. Teichman et al. (2006) characterized CJC-1295 as a long-acting GHRH analog and demonstrated that the resulting albumin conjugate exhibits a markedly extended plasma half-life of approximately 8 days [4]. Ionescu and Frohman (2006) reported that despite continuous receptor stimulation by CJC-1295 with DAC, pulsatile GH secretion persists in human studies, though with elevated trough GH and IGF-1 levels [5]. Jetté et al. (2005) provided the foundational mechanistic characterization, demonstrating that the human GHRH(1-29)-albumin bioconjugate activates the GRF receptor on the rat anterior pituitary and identifying CJC-1295 as a long-lasting GRF analog [6]. The albumin-binding strategy renders CJC-1295 with DAC particularly useful in research designs requiring sustained, tonic GHRH receptor agonism — distinct from the pulsatile-preserving profile of Mod GRF 1-29. Research-grade CJC-1295 is supplied for both research designs.
Comparative Pharmacokinetics
| Compound | Base Sequence | Key Modifications | Plasma t½ | GH Pulsatility |
|---|---|---|---|---|
| Sermorelin | GHRH(1-29) | C-terminal amide only | ~10-20 min | Fully preserved |
| Tesamorelin | GHRH(1-44) | N-terminal trans-3-hexenoyl | ~26-38 min | Preserved |
| CJC-1295 (No DAC) / Mod GRF 1-29 | GHRH(1-29) | D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ | ~30 min | Preserved |
| CJC-1295 with DAC | GHRH(1-29) | As above + DAC (albumin-binding MPA) | ~6-8 days | Pulsatility persists with elevated trough |
Research Design Implications
The choice among GHRH analogs in preclinical research depends primarily on the experimental question. Studies focused on pulsatile GH secretion physiology — including investigations of the natural ultradian pattern, GH amplitude variation, or relationships between GHRH and somatostatin opposition — typically favor short-acting Sermorelin or Mod GRF 1-29. These compounds allow the natural pulsatility of GH release to dominate the experimental window without tonic background activation.
Studies requiring sustained GHRHR activation — such as long-duration metabolic studies, body composition research, or chronic IGF-1 elevation paradigms — typically favor CJC-1295 with DAC, where weekly dosing schedules are feasible and the albumin-binding modification produces stable, prolonged receptor engagement. Tesamorelin occupies an intermediate position with its modestly extended half-life and once-daily dosing profile, making it the analog of choice for visceral adiposity research and other metabolic study designs requiring daily administration without weekly accumulation.
Researchers should also consider the combination with GHRP class peptides. GHRH analogs and growth hormone-releasing peptides (GHRPs) such as Ipamorelin act through distinct, non-competing receptor systems — GHRHR and GHSR-1a, respectively — and their co-administration in preclinical studies consistently produces additive or synergistic effects on GH secretion compared with either compound alone. A pre-combined CJC-1295 + Ipamorelin blend is available for these combination research designs.
Decision Framework for GHRH Analog Selection
To select a GHRH analog efficiently for a given research design, the following sequential decision framework is useful:
- What is the intended temporal pattern of GHRH receptor engagement? If the goal is to capture a single GH pulse — for example, in a pituitary somatotroph reserve assessment, or in a study of the immediate post-administration response — choose Sermorelin or Mod GRF 1-29. If the goal is sustained tonic receptor engagement over days, choose CJC-1295 with DAC. If once-daily administration with intermediate duration is preferred, choose Tesamorelin.
- How important is preservation of natural pulsatility? Short-acting compounds (Sermorelin, Mod GRF 1-29) preserve the natural ultradian pulsatile pattern of GH release. CJC-1295 with DAC maintains pulsatility but elevates trough GH and IGF-1. For studies in which pulsatility is the primary variable of interest, short-acting compounds are preferred.
- What is the planned co-administration profile? If pairing with a GHRP (Ipamorelin, GHRP-2, GHRP-6, or Hexarelin), the temporal overlap of the two peptides matters. Short-acting Mod GRF 1-29 paired with short-acting Ipamorelin produces a brief, well-defined dual-receptor activation window suitable for pulsatility-focused designs. CJC-1295 with DAC paired with GHRP produces sustained dual-receptor activation suitable for chronic-exposure paradigms.
- What is the duration of the experimental window? Short-duration studies (hours) can be conducted with any GHRH analog. Long-duration studies (weeks to months) favor either daily Tesamorelin administration or weekly CJC-1295 with DAC, depending on whether tonic baseline elevation is acceptable.
- What metabolic endpoint is most relevant? For visceral adipose tissue and liver fat research, Tesamorelin has the deepest preclinical and clinical literature base. For sustained IGF-1 elevation paradigms, CJC-1295 with DAC is most established. For pituitary diagnostic-style studies, Sermorelin remains the historical standard.
Common Research Pitfalls
Several recurrent pitfalls appear in GHRH analog preclinical research and should be guarded against in study design:
- Conflating Mod GRF 1-29 with CJC-1295 with DAC. Both compounds are routinely labeled “CJC-1295” in informal usage, but they have fundamentally different pharmacokinetic profiles (~30 min vs. ~6-8 days plasma half-life). Researchers should specify which compound is being used and document the source and analytical characterization.
- Sampling timing mismatch. Short-acting GHRH analogs produce GH pulses that peak 15–30 minutes after administration and decline rapidly. Plasma GH sampling at single late time points (>60 min) will substantially underestimate pulse amplitude. For Sermorelin and Mod GRF 1-29 research, frequent sampling (every 10–15 minutes for 2 hours) is appropriate.
- Failure to account for GHRHR desensitization. Sustained GHRH receptor agonism (e.g., from CJC-1295 with DAC) can produce receptor desensitization that attenuates the response to subsequent challenges. Combination studies pairing CJC-1295 with DAC with acute GHRH challenge must account for this background.
- Inappropriate dose extrapolation across compounds. Equimolar doses of different GHRH analogs do not produce equivalent biological effects because of differences in receptor binding affinity, plasma half-life, and tissue distribution. Dose-response characterization should be conducted for each compound in the experimental system.
- Inadequate analytical characterization of CJC-1295 with DAC. The DAC modification (maleimidopropionic acid group) is reactive with free thiols, so quality issues — incomplete DAC attachment, premature reaction with reducing agents in buffers — can substantially reduce the in vivo half-life. CoA documentation should explicitly characterize the DAC modification chemistry.
- Ignoring the somatostatin counter-regulatory system. Endogenous somatostatin opposes GHRH-driven GH release on an ultradian timescale, and the experimental window relative to the somatostatin cycle can dramatically affect outcomes. Where possible, GH studies should be timed during the relative somatostatin nadir.
Research Considerations for Laboratory Use
All four GHRH analogs are typically supplied as lyophilized powders at ≥98% HPLC purity. Storage at −20°C is standard for long-term archiving; reconstituted solutions should be maintained at 2–8°C and used within 2–4 weeks. Bacteriostatic water is the standard reconstitution solvent for all members of this class. CJC-1295 with DAC, owing to its albumin-binding reactive moiety, requires particular care during reconstitution to avoid premature reaction with cysteine-containing impurities. Each lot should be accompanied by a Certificate of Analysis documenting sequence identity, purity, and counterion content.
Analytical characterization deserves particular attention for the CJC-1295 with DAC compound. The DAC modification — a maleimidopropionic acid group at the C-terminus — is the most reactive functional group in the molecule and is most susceptible to quality issues. Common analytical concerns include incomplete DAC attachment during synthesis (producing peptide species lacking the albumin-binding moiety and therefore having Mod GRF 1-29–like short half-life), premature DAC hydrolysis during storage (converting the reactive maleimide to an unreactive maleamic acid), and reaction with cysteine-containing impurities or reducing agents in reconstitution buffers (consuming the DAC moiety before in vivo albumin conjugation). Mass spectrometry analysis with characteristic fragment ion verification is the most reliable confirmation of intact DAC chemistry.
For research designs using comparative dosing across GHRH analogs, molar (rather than mass) dosing is recommended to enable fair comparison across compounds of different molecular weights. Sermorelin (3358 Da), Tesamorelin (5196 Da), Mod GRF 1-29 (3367 Da), and CJC-1295 with DAC (3647 Da) all differ in molecular weight, and equimolar dosing places equivalent numbers of peptide molecules into the system. Reconstitution concentrations should be calculated to enable equimolar dosing within reasonable injection volumes.
For studies measuring downstream IGF-1 elevation as a readout of GHRH analog activity, the timing of sampling matters substantially. IGF-1 has a plasma half-life of ~15 hours bound to IGFBP-3 in the ternary complex, and IGF-1 concentrations integrate GH exposure over an extended window. Short-acting GHRH analogs (Sermorelin, Mod GRF 1-29) produce minimal IGF-1 elevation from single administrations because the GH exposure duration is too brief; sustained dosing (multiple per day or use of CJC-1295 with DAC) is required for measurable IGF-1 elevation. This relationship affects what endpoints are appropriate for each compound in research designs.
Conclusion
The four research-grade GHRH analogs — Sermorelin, Tesamorelin, CJC-1295 (No DAC), and CJC-1295 with DAC — represent a structurally elegant illustration of how iterative peptide chemistry shapes pharmacokinetic profile. Each compound has its place in preclinical research: Sermorelin for diagnostic-style probing of pituitary somatotroph reserve, Tesamorelin for daily-administration metabolic studies, Mod GRF 1-29 for short-duration pulsatility-preserving designs, and CJC-1295 with DAC for sustained-activation chronic experimental paradigms.
Researchers selecting among these compounds should match the half-life profile to the experimental question, consider potential combination strategies with GHRP-class peptides, and ensure access to high-purity, well-characterized material supported by complete analytical documentation.
Frequently Asked Questions
What is the difference between Mod GRF 1-29 and CJC-1295 with DAC?
Both peptides share the same tetrasubstituted GHRH(1-29) backbone, but CJC-1295 with DAC carries an additional maleimidopropionic acid moiety that covalently binds to serum albumin after administration. This extends the plasma half-life from approximately 30 minutes (Mod GRF 1-29) to approximately 6-8 days (CJC-1295 with DAC).
Why does pulsatility matter in GHRH analog research?
Endogenous GH is secreted in pulses, and many of its tissue effects depend on the temporal pattern rather than total exposure. Short-half-life GHRH analogs like Sermorelin and Mod GRF 1-29 preserve this pulsatile pattern in research models, while long-half-life analogs like CJC-1295 with DAC produce sustained receptor activation with elevated trough GH levels.
Can GHRH analogs be combined with GHRP-class peptides in research?
Yes. GHRH analogs and GHRP-class compounds such as Ipamorelin act at distinct receptors (GHRHR vs. GHSR-1a) and have been shown in preclinical and clinical research literature to produce additive or synergistic effects on GH secretion when administered together.
What is the purity standard for research-grade GHRH analogs?
Research-grade GHRH analog peptides should meet ≥98% purity by HPLC, with mass spectrometry confirmation of identity and characterization of any side-chain modifications (e.g., the DAC moiety on CJC-1295 with DAC).
Why does Tesamorelin use a trans-3-hexenoyl group instead of an Aib substitution?
Tesamorelin’s N-terminal trans-3-hexenoyl lipid moiety achieves DPP-4 resistance by sterically blocking access to the Tyr¹-Ala² peptide bond while keeping the full 44-residue native GHRH sequence intact. This is a different engineering strategy than the D-Ala² substitution used in Mod GRF 1-29 (which alters stereochemistry at position 2) or the Aib² substitution used in GLP-1 receptor agonists (which adds geminal dimethyl steric bulk). Each approach achieves the same functional goal — DPP-4 resistance — through distinct chemistry.
How does the DAC moiety on CJC-1295 work chemically?
The DAC moiety on CJC-1295 with DAC is a maleimidopropionic acid (MPA) group attached at the C-terminus. After subcutaneous administration, the maleimide reacts covalently with a free thiol group on circulating serum albumin (specifically Cys-34 of albumin), forming a stable thioether bond. The resulting peptide-albumin conjugate is protected from renal filtration and protease cleavage, extending the plasma half-life from ~30 minutes (unconjugated Mod GRF 1-29) to approximately 6-8 days.
Can the four GHRH analogs be used interchangeably in research designs?
No. Although all four share the same primary mechanism (GHRH receptor agonism), they differ substantially in plasma half-life, pulsatility preservation, dosing frequency, and tissue distribution. The choice between Sermorelin, Tesamorelin, Mod GRF 1-29, and CJC-1295 with DAC must be guided by the specific experimental question — most importantly, whether the design requires pulsatile or sustained GH receptor engagement.
What is the relationship between GHRH analogs and somatostatin in research designs?
Endogenous GHRH and somatostatin oppose one another in the hypothalamic-pituitary regulation of GH release. GHRH stimulates GH synthesis and release; somatostatin inhibits it. In research designs using GHRH analogs, the experimental window relative to the somatostatin ultradian rhythm influences the observed GH response — administration during the somatostatin nadir produces larger GH pulses than administration during somatostatin peaks. Many preclinical studies time GHRH analog administration accordingly.
Are GHRH analogs species-specific in their receptor activity?
Human GHRH(1-29) is well-conserved across mammalian species in its biological activity at the GHRHR, and Sermorelin (human GHRH(1-29)) is active in rats, mice, and other commonly used laboratory species. However, there are species differences in DPP-4 activity and renal clearance that can affect the observed half-life of GHRH analogs in different animal models. Researchers should consult species-specific pharmacokinetic literature when extrapolating dosing protocols across species.
References
- Walker RF, Codd EE, Barone FC, et al. Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man. Peptides. 1989;10(4):793–797. PMID: 2546126.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139–157. PMID: 18031173.
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240–247. PMID: 22298602.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16352683.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. PMID: 17018654.
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. PMID: 15817669.
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290–E1294. PMID: 16822960.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. PMID: 19243281.
- Thorner MO, Reschke J, Chitwood J, et al. Acceleration of growth in two children treated with human growth hormone-releasing factor. N Engl J Med. 1985;312(1):4-9. PMID: 3917304.
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038357.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. Review of GHRH analog and GHRP research applications. PMID: 28526632.
Explore our lab-tested Sermorelin, Tesamorelin, and CJC-1295 → /product/sermorelin/ | /product/tesamorelin/ | /product/cjc-1295/
